PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-03-05
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 0.00 shares.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 0.00 shares.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2024-09-30 was 0.00 shares.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-06-30 was 0.00 shares.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-05 | 0.00 shares 10-K · filed 2026-03-05 | |
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-13 | 0.00 shares 10-Q · filed 2025-11-13 | ||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-13 | 0.00 shares 10-Q · filed 2025-11-13 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |